Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510972-19-00

Acronym

UniMS23_0018

Enrollment

Registered

2025-02-07

Start date

2025-03-13

Completion date

2025-07-25

Last updated

2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary mediastinal large B-cell lymphoma (PMBCL)

Brief summary

CMR rate at 3 months from axicabtagene ciloleucel infusion based on disease assessment by PET-CT or PET-MRI according to Deauville and Lugano Classification

Interventions

DRUGYESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
CMR rate at 3 months from axicabtagene ciloleucel infusion based on disease assessment by PET-CT or PET-MRI according to Deauville and Lugano Classification	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026